The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: Studies in gene-knockout mice

Gastroenterology

Volumn 124, Issue 5, 2003, Pages 1500-1508

  Theodorakis, Nicholas G ^a   Wang, Yi Ning ^a   Skill, Nicholas J ^a   Metz, Matthew A ^a   Cahill, Paul A ^b   Redmond, Eileen M ^a   Sitzmann, James V ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA FLOW; ARTICLE; CONTROLLED STUDY; GENE; GENE MUTATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NOS2 GENE; NOS3 GENE; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; VEIN LIGATION; WILD TYPE;

EID: 0037621928     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00280-4     Document Type: Article

References (49)

1. Lebrec D, Bataille C, Bercoff E, Valla D. Hemodynamic changes in patients with venous obstruction. Hepatology 1983;3:550-553.
2. Reichen J. Liver function and pharmacological considerations in the pathogenesis and treatment of portal hypertension. Hepatology 1990;11:1066-1078.
3. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001;89:221-231.
4. Benoit JN, Womack WA, Hernandez L, Granger DN. "Forward" and "backward" flow mechanisms of portal hypertension: relative contributions in the rat model of portal vein stenosis. Gastroenterology 1985;89:1092-1096.
5. Kiel JW, Pitts L, Benoit JN, Granger DN, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal hypertensive rats. Am J Physiol 1985;248:G192-G195.
6. Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, Arroyo V, Piulats J, Rivera F, Jodes J. Impaired responsiveness to angiotensin II experimental cirrhosis: role of nitric oxide. Hepatology 1993;18:367-372.
7. Cahill PA, Foster CL, Redmond EM, Gingalewski C, Wu Y, Sitzmann JV, Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995;22:598-606.
8. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-293.
9. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998;28:1467-1473.
10. Bruix J, Bosch J, Kravetz D, Mastai R, Rodes J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-435.
11. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, Sitzmann JV. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: Role in the hyperdynamic circulation. Hepatology 1998;27:20-27.
12. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991;337:776-778.
13. Lee FY, Colombato LA, Albillos A, Groszmann RJ. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
14. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-239.
15. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996;25:370-378.
16. Moncada S, Palmer PM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
17. Gadano AC, Sogni P, Heller J, Moreau R, Bories PN, Lebrec D. Vascular nitric oxide production during the development of two experimental models of portal hypertension. J Hepatol 1999;30:896-903.
18. Kaviani A, Ohta M, Itani R, Sander F, Tarnawski AS, Sarfeh IJ. Tumor necrosis factor-alpha regulates inducible nitric oxide synthase expression in the portal hypertensive gastric mucosa of the rat. J Gastrointest Surg 1997;1:371-376.
19. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996;93:13176-13181.
20. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A 1995;92:10688-10692.
21. Ackerman Z, Karmeli F, Amir G, Rachmilewitz D. Gastric and colonic inflammatory and vasoactive mediators in experimental portal hypertension. Liver 1996;16:12-18.
22. Schwarz SI. Liver. In: Schwarz SI, Shires GT, Spencer FC, Daly JM, Fisher JE, Galloway AC, eds. Principles of surgery. 7th ed. New York: MacGraw-Hill, 2000;1416.
23. Fluorescence Microsphere Resource Center (1999). Manual for Using Fluorescent Microspheres to Measure Organ Perfusion (http://fmrc.pulmcc.washington.edu/). Accessed October 1, 1999.
24. Glenny RW, Bernard S, Brinkley M. Validation of fluorescent-labeled microspheres for measurement of regional organ perfusion. J Appl Physiol 1993;74:2585-2597.
25. Richer CR, Domergue V, Gervais M, Bruneval P, Giudicelli J-F. Fluorospheres for cardiovascular phenotyping genetically modified mice. J. Cardiovascular Pharmacology 2000;36:394-404.
26. Geraghty JG, Anderson WJ, Carter DC. Portal venous pressure, and portosystemic shunt in experimental portal hypertension. Am J Physiol 1989;257:G52-G57.
27. Sikuler E, Groszmann RJ. Hemodynamic studies in long- and short-term portal hypertensive rats: the relationship to systemic glucagon levels. Hepatology 1986;6:414-418.
28. Campbell KA, Wu YP, Sitzmann JV. Modulation of portosystemic shunting by prostacyclin in portal hypertension. Curr Surg 1990;47:17-19.
29. Cahill PA, Wu Y, Sitzmann JV. Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits. J Clin Invest 1994;93:2691-2700.
30. Kanwar S, Kubes P, Tepperman BL, Lee SS. Nitric oxide synthase activity in portal-hypertensive and cirrhotic rats. J Hepatol 1996;25:85-89.
31. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-541.
32. Hartleb M, Michielsen PP, Dziurkowska-Marek A. The role of nitric oxide in portal hypertensive systemic and portal vascular pathology. Acta Gastroenterol Belg 1997;60:222-232.
33. Ramsay MA, Spikes C, East CA, Lynch K, Hein HA, Ramsay KJ, Klintmalm GB. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999;90:299-301.
34. Woitas RP, Heller J, Stoffel-Wagner B, Spengler U, Sauerbruch T. Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepatology 1997;26:858-864.
35. Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999;277:G463-G468.
36. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-G1051.
37. Tsugawa K, Hashizume M, Migou S, Kishihara F, Kawanaka H, Tomikawa M, Tanoue K, Sugimachi K. Role of Nitric oxide and endothelin-1 in a portal hypertensive rat model. Scand J Gastroenterol 2000;35:1097-1105.
38. Bandi JC, Fernandez M, Bernadich C, De Lacy AM, Garcia-Pagan JC, Bosch J, Rodes J. Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. J Hepatol 1999;31:719-724.
39. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992;263:G544-G550.
40. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001;34:644-650.
41. Mizumoto M, Arii S, Furutani M, Nakamura T, Ishigami S, Monden K, Ishiguro S, Fujita S, Imamura M. NO as an indicator of portal hemodynamics and the role of iNOS in increased NO production in CC14-induced liver cirrhosis. J Surg Res 1997;70:124-133.
42. Genesca J, Gonzalez A, Segura R, Catalan R, Marti R, Varela E, Cadelina G, Martinez M, Lopez-Talavera JC, Esteban R, Groszmann RJ, Guardia J. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999;94:169-177.
43. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, Hou MC, Chan CC, Lee SD. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci (Lond) 1997;93:219-225.
44. Chu CJ, Lee FY, Wang SS, Chang FY, Lin HC, Lu RH, Wu SL, Chan CC, Tai CC, Lai IN, Lee SD. Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension. J Hepatol 1999;30:1105-1111.
45. Sitzmann JV, Li SS, Adkinson NF. Evidence for role of prostacyclin as a systemic hormone in portal hypertension. Surgery 1991;109:149-153.
46. Wu Y, Burns RC, Sitzmann JV. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology 1993;18:1416-1421.
47. Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, Rodes J. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats; influence in nitric oxide biosynthesis. Gastroenterology 1996;110:1529-1535.
48. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993;90:7240-7244.
49. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol 2002;283:G1074-G1081.